Blood–brain barrier permeable β-blockers linked to lower risk of Alzheimer’s disease in hypertension

Alzheimer's disease is a neurodegenerative disorder in which the pathological accumulation of amyloid-β and tau begins years before symptom onset. Emerging evidence suggests that β-blockers (β-adrenergic antagonists) increase brain clearance of these metabolites by enhancing CSF flow. Our objec...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaman, Emily Eufaula, Bonde, Anders Nissen, Larsen, Sara Marie Ulv, Ozenne, Brice, Lohela, Terhi Johanna, Nedergaard, Maiken, Gíslason, Gunnar Hilmar, Knudsen, Gitte Moos, Holst, Sebastian Camillo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976965/
https://www.ncbi.nlm.nih.gov/pubmed/35196379
http://dx.doi.org/10.1093/brain/awac076

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9976965/
https://www.ncbi.nlm.nih.gov/pubmed/35196379
http://dx.doi.org/10.1093/brain/awac076

Ejemplares similares